Manufacturer
DUOPHARMA MANUFACTURING (BANGI) SDN BHD
Contents
Ketoconazole
Indication
Systemic fungal infections, Cushing's syndrome.
Instruction
Should be taken with food.
Drug interaction
Increased risk of hyperkalaemia and hypotension with eplerenone. Increased risk of hepatotoxicity and QTc interval prolongation with telithromycin and clarithromycin Increased risk of oedema and CHF with felodipine and nisoldipine. Increased risk of liver damage with paracetamol. May reduce absorption with antacids, antimuscarinics, PPIs, H2-receptor antagonists. May decrease plasma concentration with CYP3A4 inducers (e.g. rifampicin, rifabutin, carbamazepine, phenytoin, isoniazid, nevirapine, mitotane). May increase serum level with CYP3A4 inhibitors (e.g. ritonavir-boosted darunavir and fosamprenavir). May increase plasma concentrations of buprenorphine, alfentanil, fentanyl, oxycodone, digoxin, apixaban, warfarin, cilostazol, repaglinide, praziquantel, saxaliptin, isavuconazole, eletriptan, buspirone, aripiprazole, reboxitine, risperidone, midazolam (IV), maraviroc, indinavir, nadolol, verapamil, aliskiren, bosentan, domperidone, naloxegol, ciclosporin, budesonide, dexamethasone, fluticasone, sildenafil, vardenafil, cinacalcet, ibrutinib, busulfan, docetaxel, vinca alkaloids (e.g. vincristine, vinblastine). May increase risk of QTc interval prolongation with haloperidol, salmeterol, ebastine, pasireotide and tolterodine.Potentially Fatal: Increased risk of QT prolongation and ventricular tachyarrhythmia (including torsade de pointes) with dronedarone, disopyramide, quinidine, dofetilide, methadone, cisapride, pimozide, sertindole, ranolazine, mizolastine, halofantrine and saquinavir/ritonavir. May increase risk of myopathy including rhabdomyolysis with HMG-CoA reductase inhibitors (e.g. lovastatin, simvastatin). May potentiate or prolong sedation and respiratory depression with oral midazolam, triazolam and alprazolam. Increased risk of bleeding with dabigatran. May increase risk of ergotism and vasospastic events with ergot alkaloids (e.g. ergometrine, ergotamine). May increase plasma concentrations of irinotecan, lurasidone, quetiapine, everolimus, sirolimus, tolvaptan, paritaprevir/ombitasvir; colchicine, fesoterodine and solifenacin (patient with renal impairment). Increase risk of adverse effect with colchicine.
Malaysia
